Harpoon Therapeutics

$HARP is down nearly 20% as of this posting. Most likely due to the fact the AbbVie has recently informed them that they will not be exercising their exclusive licensing option for Harpoon Therapeutics’ HPN217

Share This Article

 

About the Author

Harpoon Therapeutics

Joey Ramson